Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	2 shs
GBIO Generation Bio	$0.39 +8.4%	$0.43	$0.32 ▼ $4.34	$26.16M	2.76	299,747 shs	901,095 shs
HRTX Heron Therapeutics	$2.05 -2.8%	$2.18	$1.04 ▼ $3.93	$312.76M	1.33	2.31 million shs	2.70 million shs
RIGL Rigel Pharmaceuticals	$18.61 -0.9%	$18.53	$7.48 ▼ $29.82	$332.51M	1.34	211,859 shs	218,483 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	+0.05%
GBIO Generation Bio	+11.23%	-4.48%	+0.10%	-38.03%	-86.94%
HRTX Heron Therapeutics	-2.84%	-3.76%	+7.33%	+23.49%	-25.99%
RIGL Rigel Pharmaceuticals	-1.06%	-2.62%	+11.57%	-10.70%	+89.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	3.4043 of 5 stars	3.5	4.0	0.0	0.0	1.9	3.3	1.3
HRTX Heron Therapeutics	3.7321 of 5 stars	3.5	0.0	0.0	4.2	3.3	1.7	0.6
RIGL Rigel Pharmaceuticals	2.4104 of 5 stars	3.2	1.0	0.0	0.0	2.5	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	2.00	Hold	$65.00	0.05% Upside
GBIO Generation Bio	3.00	Buy	$7.33	1,778.42% Upside
HRTX Heron Therapeutics	3.00	Buy	$5.50	168.29% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	95.59% Upside

Current Analyst Ratings Breakdown

Latest HRTX, RIGL, GBIO, and ALPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
4/11/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/10/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/17/2025	GBIO Generation Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/14/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/14/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/6/2025	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $55.00
3/5/2025	RIGL Rigel Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $24.00
3/5/2025	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
2/28/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
GBIO Generation Bio	$19.89M	1.32	N/A	N/A	$3.07 per share	0.13
HRTX Heron Therapeutics	$148.52M	2.11	N/A	N/A	($0.23) per share	-8.91
RIGL Rigel Pharmaceuticals	$179.28M	1.85	N/A	N/A	($1.64) per share	-11.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
GBIO Generation Bio	-$126.61M	-$1.08	N/A	N/A	N/A	-782.86%	-104.85%	-49.54%	N/A
HRTX Heron Therapeutics	-$110.56M	-$0.06	N/A	N/A	N/A	-20.31%	N/A	-12.72%	N/A
RIGL Rigel Pharmaceuticals	-$25.09M	$2.07	132.94	17.72	N/A	2.46%	-14.80%	3.03%	N/A

Latest HRTX, RIGL, GBIO, and ALPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	GBIO Generation Bio	-$0.25	-$0.22	+$0.03	-$0.22	$1.70 million	$8.72 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million
3/19/2025	Q4 2024	GBIO Generation Bio	-$0.31	-$0.32	-$0.01	-$0.32	$2.92 million	$4.19 million
3/4/2025	Q4 2024	RIGL Rigel Pharmaceuticals	$0.30	$0.80	+$0.50	$0.80	$57.59 million	$57.60 million
2/27/2025	Q4 2024	HRTX Heron Therapeutics	-$0.03	$0.02	+$0.05	$0.02	$37.37 million	$40.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	9.56	9.56
GBIO Generation Bio	N/A	6.34	6.34
HRTX Heron Therapeutics	N/A	2.28	1.74
RIGL Rigel Pharmaceuticals	N/A	1.96	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
GBIO Generation Bio	95.22%
HRTX Heron Therapeutics	80.01%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
GBIO Generation Bio	21.80%
HRTX Heron Therapeutics	5.76%
RIGL Rigel Pharmaceuticals	9.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	Optionable
GBIO Generation Bio	150	67.01 million	52.70 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.33 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.02 million	Optionable

HRTX, RIGL, GBIO, and ALPN Headlines

Recent News About These Companies

Upgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Forecasts

May 11 at 4:20 PM | finance.yahoo.com

B. Riley Expects Reduced Earnings for Rigel Pharmaceuticals

May 11 at 8:42 AM | marketbeat.com

HC Wainwright Has Optimistic Outlook of RIGL Q2 Earnings

May 11 at 8:42 AM | marketbeat.com

HC Wainwright Issues Positive Outlook for RIGL Earnings

May 11 at 2:01 AM | americanbankingnews.com

B. Riley Research Analysts Cut Earnings Estimates for RIGL

May 11 at 2:01 AM | americanbankingnews.com

Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Target Price at $36.40

May 11 at 1:13 AM | americanbankingnews.com

B. Riley Equities Analysts Lift Earnings Estimates for RIGL

May 10 at 8:34 AM | marketbeat.com

Equities Analysts Offer Predictions for RIGL Q3 Earnings

May 10 at 8:07 AM | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Hold" by Analysts

May 10 at 3:11 AM | marketbeat.com

Rigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting Next

May 9, 2025 | uk.finance.yahoo.com

Earnings Estimates Rising for Rigel (RIGL): Will It Gain?

May 9, 2025 | zacks.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target Raised to $23.00

May 9, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Estimate for RIGL Earnings

May 9, 2025 | americanbankingnews.com

Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet

May 8, 2025 | zacks.com

Rigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | finanznachrichten.de

Why Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 27.08%

May 8, 2025 | aaii.com

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 7, 2025 | seekingalpha.com

Rigel Pharmaceuticals (RIGL) Price Target Raised by Cantor Fitzgerald | RIGL Stock News

May 7, 2025 | gurufocus.com

Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance

May 7, 2025 | msn.com

Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Report Preview: What To Expect

May 7, 2025 | finance.yahoo.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Voya Investment Management LLC

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, RIGL, GBIO, and ALPN Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Generation Bio NASDAQ:GBIO

$0.39 +0.03 (+8.44%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$0.39 +0.00 (+0.92%)

As of 05/12/2025 07:59 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Heron Therapeutics NASDAQ:HRTX

$2.05 -0.06 (-2.84%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$2.04 0.00 (-0.24%)

As of 04:38 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$18.61 -0.16 (-0.85%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$18.75 +0.14 (+0.75%)

As of 04:48 AM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time